Cormark upgraded shares of Extendicare (TSE:EXE – Free Report) to a moderate buy rating in a research note released on Wednesday,Zacks.com reports.
EXE has been the subject of several other reports. TD Securities upped their target price on Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a report on Thursday, November 14th. Royal Bank of Canada raised their target price on shares of Extendicare from C$9.50 to C$11.00 and gave the stock a “sector perform” rating in a report on Thursday, November 28th. Finally, BMO Capital Markets set a C$11.00 price target on shares of Extendicare and gave the company a “market perform” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Extendicare currently has a consensus rating of “Hold” and an average price target of C$10.25.
View Our Latest Stock Report on EXE
Extendicare Stock Performance
Extendicare Dividend Announcement
The business also recently declared a monthly dividend, which will be paid on Monday, March 17th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.04 per share. This represents a $0.48 annualized dividend and a dividend yield of 4.15%. The ex-dividend date is Friday, February 28th. Extendicare’s dividend payout ratio is currently 61.20%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Read More
- Five stocks we like better than Extendicare
- Which Wall Street Analysts are the Most Accurate?
- 3 Beauty Stocks Off to an Ugly Start—Can 1 Stage a Comeback?
- What is Short Interest? How to Use It
- Fastenal : Growth Trends, Challenges & Key Investment Insights
- Top Stocks Investing in 5G Technology
- 2 Auto Stocks to Let Go and 1 Worth Buying for the Long Haul
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.